BMCM
ABBV icon

Burns Matteson Capital Management’s AbbVie ABBV Stock Holding History

Burns Matteson Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,400
Closed -$53.5K – 194
2025
Q4 		$53.5K Buy
+1,400
New +$319K 0.02% 197

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Burns Matteson Capital Management's ABBV Position: Q1 2026 in Review

Burns Matteson Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 11,328 shares — an estimated $125K sold.

Burns Matteson Capital Management first reported a position in ABBV in Q1 2021 and held it in 16 quarters. The position peaked at $861K in Q4 2021. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Burns Matteson Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Burns Matteson Capital Management sold 11,328 AbbVie shares in Q1 2026, an estimated $125K.
  • Burns Matteson Capital Management first reported a position in AbbVie in Q1 2021 and held it in 16 quarters.
  • Burns Matteson Capital Management's AbbVie position peaked at $861K in Q4 2021.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Burns Matteson Capital Management's 13F filing for Q1 2026, filed 15 May 2026.